Paula Schaiquevich1, Armida W Fabius, Jasmine H Francis, Guillermo L Chantada, David H Abramson. 1. *Clinical Pharmacokinetics Unit, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina; †National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina; ‡Department of Ophthalmology, VU University Medical Center, Amsterdam, the Netherlands; §Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York; and ¶Service of Hematology-Oncology, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.
Abstract
PURPOSE: To review preclinical and clinical pharmacokinetic studies of the three most important chemotherapy drugs used for intraocular retinoblastoma and the contribution of the reported results to optimize treatment. METHODS: Systemic review of pharmacokinetic studies identified by a literature search at Pubmed using the keywords carboplatin, melphalan, topotecan, intravitreal, ophthalmic artery chemosurgery, pharmacokinetics, and retinoblastoma. RESULTS: A total of 21 studies were reviewed for assessing the preclinical and clinical pharmacokinetics of carboplatin, topotecan, and melphalan delivered by intravenous, periocular, ophthalmic artery, and intravitreal routes. Some preclinical studies were done before translation to the clinics. Others, despite encouraging preclinical data as reported for periocular topotecan did not correlate with clinical use. In addition, as was the case for melphalan after ophthalmic artery chemosurgery and despite nonfavorable preclinical information, some routes of drug delivery are clinically effective. Besides topotecan, complete knowledge of the pharmacokinetics of melphalan and carboplatin is still lacking. CONCLUSION: Pharmacokinetic knowledge of chemotherapy may aid to guide retinoblastoma treatment in favor of safety and efficacy. Nonetheless, results obtained in preclinical models should be translated with care to the clinics.
PURPOSE: To review preclinical and clinical pharmacokinetic studies of the three most important chemotherapy drugs used for intraocular retinoblastoma and the contribution of the reported results to optimize treatment. METHODS: Systemic review of pharmacokinetic studies identified by a literature search at Pubmed using the keywords carboplatin, melphalan, topotecan, intravitreal, ophthalmic artery chemosurgery, pharmacokinetics, and retinoblastoma. RESULTS: A total of 21 studies were reviewed for assessing the preclinical and clinical pharmacokinetics of carboplatin, topotecan, and melphalan delivered by intravenous, periocular, ophthalmic artery, and intravitreal routes. Some preclinical studies were done before translation to the clinics. Others, despite encouraging preclinical data as reported for periocular topotecan did not correlate with clinical use. In addition, as was the case for melphalan after ophthalmic artery chemosurgery and despite nonfavorable preclinical information, some routes of drug delivery are clinically effective. Besides topotecan, complete knowledge of the pharmacokinetics of melphalan and carboplatin is still lacking. CONCLUSION: Pharmacokinetic knowledge of chemotherapy may aid to guide retinoblastoma treatment in favor of safety and efficacy. Nonetheless, results obtained in preclinical models should be translated with care to the clinics.
Authors: Martina Kodetova; Radka Hobzova; Jakub Sirc; Jiri Uhlik; Katerina Dunovska; Karel Svojgr; Ana-Irina Cocarta; Andrea Felsoova; Ondrej Slanar; Martin Sima; Igor Kozak; Pavel Pochop Journal: Pharmaceutics Date: 2022-04-20 Impact factor: 6.525
Authors: Jennifer Nadelmann; Jasmine H Francis; Scott E Brodie; Engjel Muca; David H Abramson Journal: Br J Ophthalmol Date: 2020-07-14 Impact factor: 5.908
Authors: Sruti S Akella; Jasmine H Francis; Andrea Knezevic; Irina Ostrovnaya; Y Pierre Gobin; Danielle Friedman; Edith Guarini; Lindsey Eibeler; Federica Catalanotti; David H Abramson Journal: PLoS One Date: 2018-05-07 Impact factor: 3.240
Authors: Fairooz P Manjandavida; Christina Stathopoulos; Jing Zhang; Santhosh G Honavar; Carol L Shields Journal: Indian J Ophthalmol Date: 2019-06 Impact factor: 1.848
Authors: Jessica V Kaczmarek; Carley M Bogan; Janene M Pierce; Yuankai K Tao; Sheau-Chiann Chen; Qi Liu; Xiao Liu; Kelli L Boyd; M Wade Calcutt; Thomas M Bridges; Craig W Lindsley; Debra L Friedman; Ann Richmond; Anthony B Daniels Journal: Invest Ophthalmol Vis Sci Date: 2021-11-01 Impact factor: 4.799